The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally. The study will evaluate biomarkers for epigenetic aging and immunosenescence, as well as evaluate established clinical measures and risk factors for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and also infectious diseases, including flu and COVID-19.
The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals. There will also be control groups that enable testing of biomarker variability and the contribution of individual medications within the combination treatment.
The objective of the study is to obtain information needed for designing an effective personalized and adaptive treatment regimen for a larger and more diverse study population, and to obtain additional proof of principle for the new use of the medications and biomarkers for preventive medicine. The duration of treatment in the TRIIM-X trial will be 12 months.

Start Date23 Nov 2020

Sponsor / Collaborator

Intervene Immune, Inc.

IRCT2015070210599N4 / CompletedPhase 2IIT

Comparison of intra-articular injection of platelet rich plasma (PRP) versus combined PRP/somatropin on pain and joint range of motion in patients with knee osteoarthritis

Start Date22 Jun 2015

Sponsor / Collaborator-

NCT01438801 / WithdrawnPhase 4

Predictive Value of Baseline and Stimulated Serum IGF-1 and IGFBP-3 During a Dose-escalation IGF-1 Generation Test for the 1 Year Growth Response to Growth Hormone (GH) Therapy in Short Children With Low IGF-1 and a Normal GH Peak in a Provocation Test

The evaluation of a standardized diagnostic test to predict the growth response in a 1 year trial with Growth Hormone (GH) treatment (carried out in the context of regular patient care) in non GH deficient short children with low serum insulin-like growth factor-1 (IGF-1).

Start Date01 May 2013

Sponsor / Collaborator

Ipsen SA

100 Clinical Results associated with Somatropin(Genentech, Inc.)

100 Translational Medicine associated with Somatropin(Genentech, Inc.)

100 Patents (Medical) associated with Somatropin(Genentech, Inc.)

251

Literatures (Medical) associated with Somatropin(Genentech, Inc.)

31 Dec 2024·JOURNAL OF MEDICAL ECONOMICS

Critical appraisal on “Assessing the cost-effectiveness of once-weekly somatrogon vs. daily somatropin for pediatric growth hormone deficiency”

Article

Author: Masseria, Cristina ; Roeder, Claudia

31 Dec 2024·JOURNAL OF MEDICAL ECONOMICS

Authors’ response to a critical appraisal on “Assessing the cost-effectiveness of once-weekly somatrogon vs. daily somatropin for pediatric growth hormone deficiency”

Article

Author: Kongnakorn, Thitima ; Rivolo, Simone ; Fahey, Marion ; Peter, Balazs

01 Sep 2024·Endocrine Practice

Impact of Daily Growth Hormone Adherence on Height Velocity Among Children With Growth Hormone Deficiency (GHD)

Article

Author: Gupta, Anu ; Wogen, Jenifer ; Shrestha, Swastina ; Miller, Bradley S ; Parzynski, Craig ; Alvir, Jose ; Benjumea, Darrin ; Kelkar, Mona ; Wajnrajch, Michael ; Jhingran, Priti ; Loftus, Jane

OBJECTIVE:

To describe adherence to daily somatropin treatment and impact on height velocity within 1 year of treatment start among patients with pediatric growth hormone deficiency in a real-world US population.

METHODS:

This retrospective cohort study included pediatric patients aged ≥3 years to <16 years with pediatric growth hormone deficiency prescribed somatropin by a pediatric endocrinologist at a US-based center of excellence between January 1, 2015 and December 31, 2020. Patient data were collected using hospital electronic health records linked to a specialty pharmacy patient prescription records. Adherence, evaluated over 12 months, was measured using the proportion of days covered metric and patients were categorized as adherent if their proportion of days covered ≥80%. Height velocity was annualized to compare across adherent and nonadherent patients.

RESULTS:

One hundred eighty-one patients were identified and included in this study, of which 70.2% were male,73.5% were white, and mean age (standard deviation [SD]) at index was 12.1 (2.8). In the height velocity analysis, 174 patients were included and the mean (SD) annualized change in height was 10.2 (5.7) cm/y in the adherent group (n = 108) and 9.8 (7.6) in the nonadherent group (n = 66). The difference in height velocity between the groups was not statistically significant.

CONCLUSIONS:

Minor improvements in average height velocity were observed in the patient group who were adherent to somatropin therapy, although not statistically significant. Lack of observed significance may be due to small sample sizes, short observation period, a likely heterogenous population in terms of growth hormone prescribing, data bias due to single-center origin, or potential patient misclassification.

News (Medical) associated with Somatropin(Genentech, Inc.)

30 Oct 2024

·www.globenewswire.com

Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in constant currencies (from mid- to high-single digit) and core EBITDA margin² guidance of around 20% confirmed Basel, October 30, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the third quarter and nine months ended September 30, 2024. For the third quarter, net sales were USD 2.6 billion, an increase of 12% in constant currencies compared to the same quarter of the prior year. For the first nine months of 2024, net sales were USD 7.6 billion, an increase of 9% in constant currencies compared to the prior year. Richard Saynor, Chief Executive Officer of Sandoz, said: “We remain focused on execution, meeting key milestones in our biosimilars business and progressing on our journey as a standalone company. In recent months, we received approval for Pyzchiva® and Enzeevu™ in the US, launched Pyzchiva® in Europe and see continued strong uptake of Hyrimoz® in the US. “Net sales growth was achieved across generics and biosimilars, with generics accelerating in the third quarter and strong double-digit biosimilars growth in both the third quarter and first nine months. Additionally, all three regions contributed to this strong performance. We expect momentum in our business to continue, driving margin expansion through favorable product mix and leveraging our cost base. We have further advanced on our path to simplifying our business, including progression on the transformation program we launched earlier this year.” THIRD-QUARTER AND NINE-MONTH SALES Net sales for the third quarter were USD 2.6 billion, up 12% in constant currencies, compared to the third quarter of 2023. Volume contributed 13 percentage points of growth. This was partially offset by price erosion of 1 percentage point. Biosimilars were the key driver of growth in the quarter, while generics experienced solid demand. Growth accelerated in both businesses. Net sales for the first nine months of 2024 were USD 7.6 billion, up 9% in constant currencies compared to prior year. Volume contributed 11 percentage points of growth. This was partially offset by price erosion of 2 percentage points. The growth was primarily driven by biosimilars, with strong demand for both the base business and new in-market organic and acquired products in the US. Net sales by business Q3 2024Q3 2023 Change % 9M 20249M 2023 Change %USD millions unless indicated otherwise USDcc* USDcc*Generics 1 8541 794 34 5 5585 512 12Biosimilars 741 543 3637 2 0841 592 3132Net sales to third parties 2 5952 337 1112 7 6427 104 89 *constant currencies Generics overviewNet sales for the third quarter were USD 1.9 billion, up 4% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 5.6 billion, up 2% in constant currencies versus prior year. Growth in the Europe region accelerated in the third quarter, mainly driven by recent launches. The momentum continued in the International region, aided by demand for the antifungal agent Mycamine® and favorable pricing dynamics, partly offset by the divestment of the Chinese business. North America declined due to timing of new launches in the US. Biosimilars overviewNet sales for the third quarter were USD 741 million, up 37% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 2.1 billion, up 32% in constant currencies versus prior year. The strong double-digit biosimilars growth reflects the uptake of Hyrimoz® (adalimumab) in the US, the acquisition of Cimerli® (ranibizumab), the continued strong demand for our first-ever biosimilar, Omnitrope® (somatropin), and the launches of Tyruko® (natalizumab) and Pyzchiva® (ustekinumab) in Europe. Net sales by region Q3 2024Q3 2023 Change % 9M 20249M 2023 Change %USD millions unless indicated otherwise USDcc USDccEurope 1 3621 204 1312 3 9963 751 76North America 598 510 1718 1 7421 514 1515International 635 623 28 1 9041 839 49Net sales to third parties 2 5952 337 1112 7 6427 104 89 Europe overviewNet sales for the third quarter were USD 1.4 billion, up 12% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 4.0 billion, up 6% in constant currencies versus prior year. Strong growth in biosimilars continues, led by demand for Omnitrope® and the contribution from the recent launches of Tyruko® and Pyzchiva®. Generics momentum accelerated in the third quarter, driven by recent launches and the lapping of the strong prior-year comparison in the first half. North America overviewNet sales for the third quarter were USD 598 million, up 18% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 1.7 billion, up 15% in constant currencies versus prior year. Growth was driven by the ongoing uptake of Hyrimoz® in the US, the acquisition of Cimerli®, share gain of Omnitrope® in the US and the launch of Wyost®/Jubbonti® in Canada. This was partly offset by a decline in generics sales due to the timing of new launches in the US. International overviewNet sales for the third quarter were USD 635 million, up 8% in constant currencies, compared to the third quarter of 2023. Net sales for the first nine months were USD 1.9 billion, up 9% in constant currencies versus prior year. This was primarily a result of strong volume growth across both generics and biosimilars, contribution from the acquisition of Mycamine® in the prior year, favorable price dynamics and recent launches, partly offset by the divestment of the Chinese business in the second quarter. GUIDANCE 2024 On the back of strong momentum in its biosimilars business and solid generics demand, the company is increasing its full-year 2024 net sales guidance to high-single digit growth in constant currencies versus prior year (from mid- to high-single digit) and is confirming its core EBITDA margin guidance of around 20%. THIRD-QUARTER STRATEGIC MILESTONES Sandoz continued to execute on its strategy and passed additional milestones in its biosimilars portfolio. On July 1, the company announced the US FDA approval of biosimilar Pyzchiva® for all indications of the reference medicine. The company intends to launch Pyzchiva® in the US among the first wave of ustekinumab biosimilars in February 2025. On July 25, Sandoz announced the launch of biosimilar Pyzchiva® across Europe to treat chronic inflammatory diseases. Pyzchiva® was the first biosimilar to launch in Europe with all reference medicine strengths, including an initiation dose for Crohn’s disease. On August 12, Sandoz received FDA approval for Enzeevu™ to treat neovascular age-related macular degeneration. This approval further enhances the company’s leading US ophthalmology portfolio and increases access for patients. Launch timing will be dependent on several factors, including the progress and outcome of pending or potential litigation or any potential settlements. KEY LINKS Webcast – Live at 9am CET Analyst call presentationAnalyst consensus DISCLAIMER This media release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.This media release includes non-IFRS financial measures as defined by Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2023, Sandoz recorded net sales of USD 9.6 billion. CONTACTS Global Media Relations contacts Investor Relations contactsGlobal.MediaRelations@sandoz.comInvestor.Relations@sandoz.comSteffen Kurzawa+41 79 800 8501Laurent de Weck+41 79 795 7364Joerg E. Allgaeuer+49 171 838 4838Tamara Hackl+41 79 790 5217 SUPPORTING FINANCIAL INFORMATION Quarterly net sales 2024 Q1 2024Change % Q2 2024Change % Q3 2024Change %USD millions unless indicated otherwise USDcc USDcc USDccGenerics 1 86901 1 835-11 1 85434Biosimilars 6232121 7203537 7413637Net sales to third parties 2 49256 2 55579 2 5951112 Q1 2024Change % Q2 2024Change % Q3 2024Change %USD millions unless indicated otherwise USDcc USDcc USDcc Europe 1 32642 1 30823 1 3621312North America 52466 6202223 5981718International 642412 62759 63528Net sales to third parties 2 49256 2 55579 2 5951112 2023 Q1 2023Change % Q2 2023Change % Q3 2023Change % Q4 2023Change %USD millions unless indicated otherwise USDcc* USDcc* USDcc* USDcc* Generics 1 86826 1 85046 1 79454 1 92066Biosimilars 5161117 5331314 54374 6232926Net sales to third parties 2 38449 2 38358 2 33764 2 5431110 Q1 2023Change % Q2 2023Change % Q3 2023Change % Q4 2023Change %USD millions unless indicated otherwise USDcc* USDcc* USDcc* USDcc* Europe 1 2701016 1 2771412 1 204113 1 272104North America 496-5-3 508-4-2 510-4-3 6152020International 618-14 598-38 623312 656414Net sales to third parties 2 38449 2 38358 2 33764 2 5431110 ¹ Net sales in this document refer systematically to net sales to third parties. In the first nine months of 2023, third-party sales excluded sales to our former parent. Post spin-off, sales to our former parent are reported as third-party sales.² An explanation of non-IFRS measures can be found in the Supplementary financial information of the Half-Year Report 2024 Attachment 241030_Q3 and 9M Sales 2024_ Media Release.pdf

Drug ApprovalBiosimilarAcquisition

08 Mar 2024

·www.prnewswire.com

VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

SHANGHAI, March 7, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Administration (NMPA). Lonapegsomatropin is the first once-weekly administrated growth hormone approved by both the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of Pediatric Growth Hormone Deficiency (PGHD). Mr. Pony LU, CEO of VISEN Pharmaceuticals, said, "As the first upcoming commercial product of VISEN Pharmaceuticals, lonapegsomatropin has demonstrated statistically significantly greater efficacy than the daily hGH in the Chinese Phase 3 clinical results. The BLA acceptance represents a significant step towards the product commercialization. We believe that by continuously focusing on providing first-in-class or best-in-class products and treatments, we could provide Chinese endocrine patients with innovative therapies and achieving better treatment processes and outcomes." Lonapegsomatropin is a prodrug of somatropin administered once weekly. By leveraging the innovative technology platform TransConTM (transient conjugation), it is designed to provide sustained release of active, unmodified somatropin, the same growth hormone used in daily pediatric GHD treatments. The unmodified, unbound somatropin released from lonapegsomatropin has the identical 191 amino-acid sequence and size (22 kDa) as endogenous growth hormone. Lonapegsomatropin and TransCon technology are owned and developed by Ascendis Pharma A/S. VISEN Pharmaceuticals holds exclusive rights to develop, manufacture and commercialize lonapegsomatropin in the Greater China. Approval No.: COMU2024029/EN/PR About VISEN Pharmaceuticals VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients' need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases. VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier. For more information, please visit our website: Contact us: [email protected] SOURCE VISEN Pharmaceuticals (VISEN)

Drug ApprovalPhase 3Clinical ResultNDA

15 Jan 2024

·www.prnewswire.com

Chronic Disease Markets for Sustained Released Injectables: The Trend toward Self-Administration

DUBLIN, Jan. 15, 2024 /PRNewswire/ -- The "Chronic Disease Markets for Sustained Released Injectables" report has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for chronic disease markets for sustained release injectables. Provider organization business managers, healthcare administrators and investors will also benefit from this study. Evolving Engineered Solutions Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less. What You Will Learn What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them? What are the major factors driving sustained release injectable drug demand? What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact? How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry? What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products? In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate? What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables? Key Topics Covered: Injectable Drug Market Dynamics The Trend toward Self-Administration Injectable Drug Formulation Technology Innovation in Injectable Device Designs Therapeutic Demand Drivers Market Factors Competitive Landscape Risk Factors Sustained Release - Branded Formulation Technologies Biodegradable Polymers Branded SR Formulation Technologies Physical Process Control Methods Sustained Release Injectables - Development Factors Formulation Factors Stability Lyophilization Packaging Administration Factors SR Injectables - Product Analysis & Market Sector Forecasts Addiction Naltrexone Diabetes Exenatide Infectious Disease Interferon Hormone Deficiency Estradiol Somatropin Testosterone Metabolic Diseases Acromegaly Neurology Oncology Leukemia Lymphoma Cytarabine Prostate Pain Management Reproductive Health Fertility Endometriosis Market Profiles Companies Mentioned Alkermes Amylin AntriaBio Ascendis Pharma AstraZeneca Aurobundo Avadel Biomarin Camurus Critical Pharmaceuticals DURECT Eli Lilly Enzon Ipsen Janssen NanOlogy Novartis OctoPlus Oakwood Laboratories/PharmaSophia Pacira PhaseBio Pharmaceuticals Recipharm AB Roche Sanofi Taiwan Liposome Company Xbrane Bipharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Somatropin(Genentech, Inc.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	H01AC01	DB00052

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Renal function impairment with growth failure	EU	Ipsen Pharma SAS	15 Feb 2001
Renal function impairment with growth failure	IS	Ipsen Pharma SAS	15 Feb 2001
Renal function impairment with growth failure	LI	Ipsen Pharma SAS	15 Feb 2001
Renal function impairment with growth failure	NO	Ipsen Pharma SAS	15 Feb 2001
Dwarfism	US	Genentech, Inc.	29 Dec 1995
Idiopathic short stature	US	Genentech, Inc.	29 Dec 1995
Chronic Kidney Diseases	US	Genentech, Inc.	09 Mar 1994
Growth Disorders	US	Genentech, Inc.	09 Mar 1994
Growth hormone deficiency	US	Genentech, Inc.	09 Mar 1994
Turner Syndrome	US	Genentech, Inc.	09 Mar 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 3	US	Genentech, Inc.	01 Feb 2006
Pituitary Diseases	Phase 3	BE	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	CZ	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	DK	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	FI	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	FR	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	DE	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	GR	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	IT	Ipsen SA	01 Jun 2004
Pituitary Diseases	Phase 3	RO	Ipsen SA	01 Jun 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2021	Not Applicable	Growth hormone deficiency	201	Adherent to daily somatropin therapy	fbirakiwts(ovyuzewfhx) = jidcaafzxv sbhsvitnxz (ayjaxearvy, 8.9 - 9.9)	-	22 Sep 2021
				Non-adherent to daily somatropin therapy	fbirakiwts(ovyuzewfhx) = hitnzovzql sbhsvitnxz (ayjaxearvy, 6.6 - 8.5)
NCT00234533 (OPTIMA, CTgov)	Phase 3	Dwarfism \| Turner Syndrome \| Pituitary Diseases	251	Somatropin (rDNA origin)	vsqzlgublt(yofgkiftho) = wurmiyuvwy imztdxlgkm (ipslvhgwlc, azezttuwfb - otkblfpnie) View more	-	09 Aug 2018
ESPE2014	Not Applicable	Inflammatory Bowel Diseases	13	rhGH group	wbnxtbgiwb(bwyleisjzl) = wqpwqzymrz xfpncuvzum (voccwkrlsj )	-	18 Sep 2014
				Recombinant Human GH	wbnxtbgiwb(bwyleisjzl) = frtmhkuqfh xfpncuvzum (voccwkrlsj )
ESPE2014	Not Applicable	Dwarfism, Pituitary exon 3 deleted (d3-GHR) genetic polymorphism of GH receptor (GHR)	111	Recombinant Human GH	yycpkfseda(ffcqrnswxj) = fyewlmogqr hncwanzxkt (tncflybply ) View more	-	18 Sep 2014
				Recombinant Human GH	yycpkfseda(ffcqrnswxj) = ppxtcjuihx hncwanzxkt (tncflybply ) View more
ESPE2014	Not Applicable	Central Nervous System Cysts	12	rhGH	fbvrvfivkw(pxzigfagrc) = zjfgamwuku ebbiwaygrj (kvvjykdluk ) View more	Positive	18 Sep 2014
NCT00283595 (CTgov)	Phase 2	Binge-Eating Disorder \| Osteoporosis \| Anorexia Nervosa	21	Growth Hormone (Recombinant Human Growth Hormone Group)	gucydrfffg(xadoetpmnr) = fwiyrnxlwf kjruvwnxwj (yheykkpefd, jqexjldmqq - wnelgmqpcx) View more	-	16 Oct 2012
				Placebo (Placebo Group)	gucydrfffg(xadoetpmnr) = ndevtccjpc kjruvwnxwj (yheykkpefd, sjipjrscbv - sqeizmucau) View more
NCT00109473 (CTgov)	Phase 2	Pediatric Crohn's Disease	22	Growth Hormone (Growth Hormone Plus Cortecosteroid)	enspdvojgy(mwimsancxl) = infcphlihw zntlxodssz (lzgvwpsxpb, eugntvqqwy - jwompccija) View more	-	16 Sep 2011
				cortecosteroid (Cortecosteroids Alone)	enspdvojgy(mwimsancxl) = wpmaotcegn zntlxodssz (lzgvwpsxpb, zybehojbcb - ihiyimmvgt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis